Association of germline TYK2 variation with lung cancer and non‐Hodgkin lymphoma risk

Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate‐to‐severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarmolinsky, James, Amos, Christopher I., Hung, Rayjean J., Moreno, Victor, Burrows, Kimberley, Smith‐Byrne, Karl, Atkins, Joshua R., Brennan, Paul, McKay, James D., Martin, Richard M., Davey Smith, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
CANCER EPIDEMIOLOGY
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588593/
https://www.ncbi.nlm.nih.gov/pubmed/35747941
http://dx.doi.org/10.1002/ijc.34180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588593/
https://www.ncbi.nlm.nih.gov/pubmed/35747941
http://dx.doi.org/10.1002/ijc.34180

Ejemplares similares